26 July 2018 
EMA/506642/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kalydeco 
ivacaftor 
On 26 July 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Kalydeco. 
The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals (Europe) Ltd. 
For the tablet formulation only, the CHMP adopted an extension to the existing indication as follows: 
“Kalydeco tablets are also indicated in a combination regimen with tezacaftor 100 mg/ivacaftor 
150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who 
are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and 
have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, 
D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 
3849+10kbC→T.” 
For information, the full indications for Kalydeco tablets will be as follows:2 
“Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years 
and older and weighing 25 kg or more who have one of the following gating (class III) mutations 
in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R 
(see sections 4.4 and 5.1).  
Kalydeco tablets are also indicated for the treatment of patients with cystic fibrosis (CF) aged 18 
years and older who have an R117H mutation in the CFTR gene (see sections 4.4 and 5.1). 
Kalydeco tablets are also indicated in a combination regimen with tezacaftor 
100 mg/ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) 
aged 12 years and older who are homozygous for the F508del mutation or who are 
heterozygous for the F508del mutation and have one of the following mutations in the 
CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, 
R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Kalydeco  
EMA/506642/2018 
Page 2/2 
 
  
  
 
